Affiliation:
1. Rostov-on-Don Research Anti-Plague Institute
Abstract
Currently, great significance is attached to the preparation of diagnostic drugs based on specific immunoreagents, which include monoclonal antibodies produced by hybridomas. The use of monoclonal antibodies is one of the important approaches for the detection of pathogens of particularly dangerous infections – anthrax, brucellosis, tularemia, plague, cholera, glanders, and melioidosis. The review presents the main achievements of Russian scientists on obtaining such experimental drugs, and also pays attention to those sets of monoclonal reagents that are authorized in the Russian Federation. To date, three sets of reagents for detecting the causative agent of anthrax (latex agglutination, immunochromatographic method, multiplex immunofluorescence analysis) have been registered in our country on the basis of monoclonal antibodies; four sets of reagents for identifying the causative agent of tularemia (latex agglutination, immunochromatographic method, multiplex immunofluorescence analysis, dot-variant of enzyme immunoassay); three sets for the detection of plague microbe (enzyme immunoassay and immune chromatographic tests); five sets for cholera vibrios (slide agglutination, immunofluorescence, immune chromatographic method and enzyme immunoassay); two sets for the diagnosis of glanders and melioidosis (immunofluorescence); kits for detecting brucella have not been registered, there are only singular experimental designs. The involvement of modern drugs based on monoclonal antibodies in the diagnosis of particularly dangerous infections will improve the quality and reliability of laboratory analysis.
Publisher
Russian Research Anti-Plague Institute Microbe
Subject
Infectious Diseases,Microbiology (medical),Immunology,Microbiology,Epidemiology
Reference54 articles.
1. Al’tshuler E.P., Serebryanaya D.V., Katrukha A.G. [Production of recombinant antibodies and methods for increasing their affinity]. Uspekhi Biologicheskoy Khimii [Advances in Biological Chemistry]. 2010; 50:203–58.
2. Samartseva T.G., Oksanich A.S., Gavrilova N.F., Yakovleva I.V., Sviridov V.V., Zverev V.V. [The use of universal plasmid constructs for the production of full-length recombinant antibodies with a set specificity in eukaryotic cells]. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2018; 3:32–9. DOI: 10.36233/0372-9311-2018-3-32-39.
3. Lugovskoy A.A. [Therapeutic antibody engineering: theory and practice]. Molekulyarnaya Biologiya [Molecular Biology]. 2017; 51(6):886–98. DOI: 10.7868/S0026898417060027.
4. Karabel’sky A.V., Nemankin T.A., Ulitin A.B., Vaganov A.S., Mosina E.A., Ivanov R.A. [Development of innovative preparations of monoclonal antibodies]. Biotekhnologiya [Biotechnology]. 2017; 33(1):10–29. DOI: 10.21519/0234-2758-2017-33-1-10-29.
5. Belova E.V., Khlyntseva A.E., Dyatlov I.A., Shemyakin I.G. [The strain of hybrid cultured animal cells Mus musculus 1E6 – producer of monoclonal antibodies specific to Bacillus anthracis spores]. RF patent No. 2439148, publ. 10.01.2012 Bul. No. 1.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献